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 Methionine adenosyltransferases (MATs) are a family of highly conserved oligomers that 
catalyze the only known reaction for the synthesis of S-adenosylmethionine (AdoMet), the main 
cellular methyl donor. Their catalytic subunits exhibit a characteristic structure, organized in 
three domains formed by nonconsecutive stretches of the sequence. The active sites locate at the 
interface between subunits in the dimer with amino acids of each monomer contributing to 
catalysis. Changes in activity, oligomerization level and expression have been detected in several 
hepatic diseases; the knockout mouse for MAT1A spontaneously developing hepatocellular 
carcinoma (HCC). However, none of the patients with persistent hypermethioninemia caused by 
mutations in this gene exhibits hepatic problems, instead a few cases showing demyelination 
have been described. This chapter discusses aspects related to the structural features of these 
enzymes and the impact that the mutations found in the human MAT1A gene may have in the 
final protein structure. The influence of the redox environment in MAT folding and association is 
also analyzed, in light of the effects that drugs and metals that alter the GSH/GSSG ratio produce 
in the activity and association level. The recent report of the nuclear localization of the MAT I/III 
isoenzymes, along with their presence in tissues other than liver opened the option to MAT 
moonlighting. The possibility exists that disease development is related not only to a decrease in 
AdoMet production, but also to the role of these particular isoenzymes in different subcellular 
compartments. Therefore, the influence of MAT1A mutations, especially those leading to protein 
truncations, on folding and subcellular localization is discussed, paying special attention to the 
Hazelwood’s hetero-oligomerization hypothesis to explain the demyelination process in patients 













 The first mention of an “active methionine” capable of transmethylating in the absence of 
ATP was made in 1951 by Giulio L. Cantoni in a paper where the biosynthesis of N1-
methylnicotinamide from methionine and nicotinamide was studied [1]. The nature of this 
compound was ignored at that moment, although it was described as a product resulting from the 
reaction between ATP and methionine. In 1953, a new paper by this author described the reaction 
catalyzed by the “methionine-activating enzyme” and the chemical nature of the “active 
methionine”, S-adenosylmethionine (AdoMet)[2]. This compound was defined as an addition 
product of methionine and the adenosine moiety of ATP, having the configuration of a sulfonium 
compound in which an energy-rich bond links the methyl and the onium groups. This sulfonium 
ion is also involved in carbon-sulfur bonds with two additional groups, the 3-amino-3-
carboxypropyl and 5´-deoxyadenosyl groups that can be donated as well. In the three cases 
donation of either of these groups requires the nucleophilic attack of the corresponding carbon-
sulfur bond [3, 4]. Additionally, AdoMet can provide other groups for the synthesis of biological 
compounds (Figure 1), a fact that favors its implication in a large variety of reactions. Such a 
versatility let authors calculate that the number of reactions in which this donor participates is as 
large as that involving the use of ATP [5]. 
 Methylation reactions are of special importance due to the large number of such processes 
that take place in any cell, and that result in the main consumption of AdoMet (∼90-95%). These 
processes serve either for the synthesis of new compounds (methylation of small molecules, 
phospholipids, etc.) or for the regulation of cell function (methylation of DNA, RNA or proteins), 
and in all cases S-adenosylhomocysteine (AdoHcy) is produced [6]. AdoHcy is a potent inhibitor 
of most transmethylation reactions, but serves also as the intermediate for the synthesis of 
homocysteine (Hcy) and an important bacterial signaling molecule, Autoinducer-2 [7]. The 
aminocarboxypropyl group of AdoMet can be donated for the synthesis of the hypermodified 
tRNA nucleoside 3-(3-amino-3-carboxypropyl) uridine [8], but previous decarboxylation at this 
group is required for aminopropyl donation for the synthesis of polyamines (spermidine and 
spermine in mammals), plant hormones (ethylene), or signal molecules of Gram negative bacteria 
(N-acyl-L-homoserine lactones) [9]. Recently, a new class of proteins collectively named as 
SAM radical proteins was uncovered [10]. This family of enzymes uses the 5´-deoxyadenosyl 
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radical of AdoMet for the synthesis of vitamins (biotin), antioxidants (lipoic acid) and 
photosynthetic pigments. Other uncommon reactions involving AdoMet include the donation of 
amino groups for the synthesis of 7,8 pelargonic acid (a precursor of biotin) [11], ribosyl groups 
for queuosine synthesis [12], and carboxylic groups to lipophilic acceptors [13]. AdoMet has also 
been shown to undergo biohalogenation reactions leading to 5´-deoxy-5´-fluoroadenosine or its 
chloro-, bromo- or iodo- analogues [9].  
 AdoMet has additional roles as regulator of its own production and elimination through its 
effects on several enzymes of the methionine and the folate cycles, as well as in the trans-
sulfuration pathway. In mammals, the essential amino acid methionine is mainly metabolized in 
the liver (∼48% of the ingested amino acid in humans), where it can be used either for protein 
synthesis or by the methionine cycle (Figure 2). The first and rate-limiting step in this last 
pathway is AdoMet synthesis catalyzed by the methionine adenosyltransferase (MAT) 
isoenzymes, some of which are inhibited by the product. In human adult liver up to 8 g of 
AdoMet are produced by MATs daily [14], most of which is used as methyl donor for the 
transmethylation reactions leading to AdoHcy generation. This compound is metabolized by 
AdoHcy hydrolase leading to Hcy and adenosine, the only reversible step of the cycle that favors 
AdoHcy accumulation. Thus, elimination of the products of this reaction, Hcy and adenosine, 
controls the levels of this transmethylation inhibitor. Four are the enzymes involved in this 
removal: i) adenosine deaminase that transforms adenosine into inosine; ii) cystathionine β-
synthase (CBS) that uses Hcy and serine in a condensation reaction to render cystathione, a step 
that is activated by AdoMet; iii) methionine synthase that remethylates Hcy using as methyl 
donor 5-methyltetrahydrofolate (MTHF); and iv) betaine homocysteine mehyltransferase that 
remethylates Hcy utilizing as methyl donor the betaine provided by choline oxidation, in a step 
inhibited by AdoMet [15]. These reactions allow connection of methionine metabolism with 
other pathways such as trans-sulfuration through the CBS reaction and the folate cycle that 
includes methionine synthase. The trans-sulfuration pathway renders cysteine that is used among 
others for protein and glutathione synthesis, the GSH/GSSG ratio modulating MAT activity [16]. 
Folate recycling is also controlled by AdoMet, which inhibits methylenetetrahydrofolate 
reductase (MTHFR), and hence MTHF production. This last compound is also an inhibitor of 
glycine-N-methyltransferase, the transmethylating enzyme responsible of the largest 
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consumption of AdoMet in a key step for controlling the levels of this metabolite [17]. In 
addition to these data, AdoMet has been also involved in the regulation of several processes, 
among them apoptosis and growth [18]. The role exerted in apoptosis (protector or inducer) 
depends on the cell type under study (hepatocytes or hepatoma cells) and can be mimicked by 
one of AdoMet derivatives, methylthioadenosine (MTA). All this condensed information allows 
the reader to get a glimpse of the importance of AdoMet for all kind of cells, and hence of the 
only known route for its synthesis catalyzed by the MAT family of enzymes to which this article 
is committed.  
 
2. Methionine adenosyltransferases 
 MAT enzymes use methionine and ATP to render AdoMet and triphosphate that is 
excised into pyrophosphate and inorganic phosphate in the second part of the reaction. This 
catalysis follows a SN2 displacement mechanism, in which 95% of the Pi derives from the γ-
phosphoryl group of ATP [19]. MATs need divalent cations (Mg2+) for catalysis, and many of 
them are also activated by monovalent cations (K+). AdoMet is needed for cell survival, and 
hence MATs have been found in almost every single organism (from Mycoplasma genitalium to 
mammals) except for a few parasites that obtain the compound from their hosts [20]. Sequences 
for the catalytic subunits are very well conserved between Bacteria and Eukarya, whereas 
Archaea express highly divergent forms in which catalytic amino acids are preserved [21]. All 
the enzymes of the family characterized to date are homo-oligomers, except for mammalian 
MAT II hetero-oligomers that consist of catalytic (α2) and regulatory subunits (β) [22]. This β-
subunit, however, is also able to interact with mammalian α1 and E. coli catalytic subunits, as 
demonstrated upon its overexpression in cell culture lines and bacterial systems. Most of the 
oligomers found are tetramers, with two notable exceptions, the archaeal MATs and one 
mammalian isoenzyme known as MAT III that form dimeric associations [23].  
 Several MAT isoenzymes are expressed in diverse organisms (from Eukarya to Bacteria), 
the larger number of variants being found in plants [20]. Probably the most interesting, and best 
characterized, case is that found in mammals, where three isoenzymes exist, their main feature 
being the differences in Km values for methionine exhibited by each isoform: MAT I (homo-
tetramer) ∼100 µM, MAT II (hetero-oligomer) ∼30 µM and MAT III (homodimer) ∼1 mM [5, 
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24]. These mammalian MATs are also regulated in a dissimilar way by the reaction product, thus 
whereas MAT I and II are inhibited by AdoMet, MAT III is activated [5, 25, 26]. Since their 
discovery it was thought that MAT I and III expression was restricted to normal liver, but recent 
papers showed first their expression in pancreas [27] and later in many other tissues [28]. On the 
other hand, MAT II was known to be ubiquitous, as well as the hepatic fetal form and the 
isoenzyme expressed in hepatoma [5]. Analysis of the β-subunit expression revealed that this 
subunit appears in most tissues and that its splicing variants show a differential expression pattern 
[29]. 
  
3. Human MAT genes and their mutations.  
 The human genome contains three MAT genes, MAT1A, MAT2A and MAT2B that encode 
for the two catalytic subunits, α1 and α2, and the regulatory β-subunit, respectively. The MAT1A 
gene (∼20 kbp) localizes to the 10q22 human chromosome [30], the MAT2A gene (∼6 kbp) to the 
2p.1.1 chromosome [31] and the MAT2B gene (∼6.8 kbp) was identified in the long arm of 
chromosome 5 at the interphase between 5q34 and 5q35.1 bands [32]. Both MAT1A and MAT2A 
genes consist of eight introns and nine exons that codify for proteins of 395 amino acids [33, 34]. 
On the other hand, the MAT2B gene consists of six introns and seven exons that encode for a 
protein of 335 residues [32]. 
 Mutations in the MAT1A gene have been characterized in patients showing isolated 
persistent hypermethioninemia with methionine levels reaching 1.3 mM in some cases (35-fold 
over control levels) (Table 1)[35]. Most of these patients did not show important pathological 
symptoms, although a few cases of demyelination have been described [30, 36]. The mutations 
identified to date follow mostly a recessive autosomal inheritance trait, although Mendelian 
dominant inheritance for the G to A transition leading to the R264Hh1 mutation has been 
described [37-39](Table 1). Some of the mutations reported led to early stop codons rendering 
subunits of 91, 184, 349, 350 and 386 residues [30, 35, 36, 40, 41]. The possibility of longer 
proteins has also been reported as a result of one mutation at the stop codon [42], and a change in 
the last nucleotide of exon III that alters the splice-donor site [35]. Some of these mutated 
                                                
1 The superscript indicates the species: rat (r), human (h), E. coli (c), Methanococcus (Mj) 
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MATα1 forms have been expressed in COS-1 and/or E. coli cells to study their activity and 
association state as has been reviewed elsewhere [34, 35, 39].  
 Neonatal screenings for early detection of metabolic alterations are carried out throughout 
the world. One of these procedures carried out in Galicia, a region in the northwest of Spain, 
revealed a high incidence of persistent hypermethioninemia among the galician population 
(1/23470 newborns), the most common mutation identified being MAT1A R264Hh [43]. 
However, to date no mutations in the human MAT2A and MAT2B genes have been reported, 
although the existence of splicing variants for MAT2B in hepatocellular carcinoma (HCC) and 
HepG2 cells has been shown [29]. Four variants have been described to date, the main splicing 
forms being V1 and V2 that differ in their transcriptional initiation site. These sites locate at 
positions -203 and -2372 from the ATG codon, respectively. Thus, V2 uses a different exon I and 
the resulting proteins diverge in the 20 initial amino acids of their N-terminals. In addition, V2a 
misses the first 51 bp of exon VII, whereas V2b lacks the information of exons III-VI. Available 
functional data have been obtained only with the V1 variant, and hence information concerning 
association of the new forms with the catalytic α2 subunits, their effects on methionine affinity, 
or their putative actions on α1 subunits is lacking.   
 
4. MAT structure and impact of the human mutations. 
 Recently a review concerning the MAT structural data available has been published [23], 
and readers are referred to that publication for detailed structural information. Therefore, this 
section will focus on the location and potential structural effects of the human mutations 
described to date. The crystal structures that have been reported show common features 
concerning the α-subunit domain organization, the dimer association and the catalytic sites. The 
sequence of the α-subunits is arranged in three domains formed by non-consecutive stretches of 
the amino acid chain (Figure 3). Deletions originated by human MAT1A mutations include 
truncations leading of the loss of part of the C-terminal domain elements (386X and 350X) to 
proteins that lack information even for one complete domain of the three that are present in the 
wild type subunit (92X and 185X) (Figure 4). In addition, other truncated forms not only loss 
∼40% of the C-terminal domain, but also change the sequence of most of the remaining part of 
this domain, as well as of ∼14% of the central domain (351X) (Figure 5). The longer α-subunits 
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resulting from the stop codon mutation, should in contrast contain the information to build the 
three wild type domains, but will have a C-terminal domain ∼20% longer (X396Y-464X) (Figure 
3). On the other hand, those derived from the mutation in the splice donor site should include a 
large change in the protein sequence, and hence their structure being drastically altered. 
 Two subunits associate to form the dimer through a large flat hydrophobic surface to 
which amino acids of the three domains contribute [44, 45](Figure 6). Thus, severe truncations 
(92X and 185X) will lack most of this interaction surface, whereas more moderate effects could 
be expected for those mutations rendering shorter C-terminal domains (350X and 386X). The 
exception should be the 827insG (351X) that may impose additional difficulties for association 
derived not only from the lack of part of the C-terminal domain, but also from the change in the 
sequence starting on residue 276 (Figure 5). The effect that a longer C-terminal (X396Y-464X) 
could have on the subunit association may range from no interference with the normal interaction 
pattern to steric hindrance of part of the interacting residues. Single amino acid substitutions 
detected in patients could also affect the interaction pattern indirectly, by changing the spatial 
orientation of the chains or directly by disrupting them. This last case could be that of L42Ph and 
L305Ph mutations that occur at α-helixes H1 and H6, respectively. In addition to the large 
number of hydrophobic interactions linking monomers, there are a few polar bonds contributing 
to dimer stability [44]. Among the residues involved in this type of interactions is R264h, the 
equivalent R265r appearing bonded to E58r and T263r in the crystal structure of rat MAT I [44]. 
Several patients have the R264Hh or R261Ch mutations, which will clearly block interaction with 
E58r that involves the side chain amino group of the arginine residue. Disruption of this bond 
seems will have important consequences for dimerization as judged from studies with the 
mutated recombinant proteins. Characterization of the recombinant R264Hh mutant showed that 
the protein is a monomer exhibiting tripolyphosphatase activity [46], although analogous mutants 
prepared by others and in MATc indicated its oligomeric association [39, 47].  
 The two active sites per dimer locate between both subunits that contribute the residues 
for substrate binding and catalysis [44, 48]. Such an organization thus needs the production of a 
precise arrangement that allows placing of the catalytic residues in the correct positions for 
catalysis to proceed. Essential residues have been identified by chemical modification and in 
crystal complexes including substrates (ATP and methionine) or their analogues (AMPPNP, L-
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cisAMB, AEP)[23]. In most of the cases their role was later verified in recombinant proteins after 
site directed mutagenesis. Among them, F251r against which methionine analogues are found and 
that locates at the initial position of a short loop in the active site [44]. No single mutations at key 
residues for AdoMet synthesis have been identified to date, although some substitutions may 
indirectly affect catalysis because of their sequence or spatial proximity to the catalytic residues, 
thus explaining the reductions in activity reported. In contrast, the human mutations involving 
R264h directly perturb the phosphatase activity, as this residue has been show to orient the PPPi 
chain for hydrolysis [47]. 
 Interaction between dimers in the tetramer occurs through the central domains of the 
subunits. A few polar interactions are responsible of tetramerization, the number of which is 
lower in mammalian MATs than in the E. coli protein [44, 45]. Moreover, the interaction pattern 
seems quite different, the bacterial tetramer exhibiting a central interaction core, surrounded by a 
ring of interactions that in mammalian MAT Ir is lacking [49]. The existence of these additional 
bonds could be responsible for the higher stability exhibited by bacterial tetramers.  
 Other studies have shown cysteines as key residues for both MAT activity and dimer-
dimer association in both rat and E. coli enzymes [50, 51]. The α1-proteins contain 10 such 
residues per monomer, from which C121r locates in a loop that has been proposed to regulate the 
access of substrates to the active site [44, 52]. Chemical modification of two cysteine 
residues/monomer in MAT I/IIIr let to dissociation into inactive dimers [51, 53], a fact that has 
been further explored using single cysteine to serine mutants [54]. The results obtained indicated 
that the five residues located in the central domain (C35r-C105r) are key in dimer-dimer 
association, a result later supported by crystallographic data that showed the interface between 
dimers provided by this single domain. The sulfhydryl groups of residues C35r and C61r are 
facing each other and at disulfide bond distance, an important fact for oligomerization as it will 
be explained in the following sections [44, 49]. No human mutations at cysteine residues have 
been reported, although a couple of the substitutions identified to date include new cysteines at 
positions 264h or 199h [30, 35, 42], and the sequence change due to 827insG (351Xh) adds 6 
cysteine residues more to the remaining C-terminal domain (Figure 5). The impact that inclusion 
of a larger number of this type of amino acid could have on protein folding may be responsible 
for the low activity exhibited by the recombinant mutants. The relevance of cysteines in α2 
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proteins cannot by extrapolated from the results with α1 oligomers, since they differ in the 
cysteine content and lack equivalent residues at some positions in the central domain, among 
them C61r.  
 
5. Actual knowledge on MAT folding. 
 Most of the available data have been obtained in vitro using MAT I/IIIr, Bacillus subtilis 
and Methanococcus jannaschii MATs in unfolding and refolding experiments using denaturants 
such as urea and temperature [55-57]. Here we will refer mainly to MAT I/IIIr due to its high 
homology to the human enzyme. Refolding results indicated the need to populate an intermediate 
state to achieve the final active dimer and highlighted the importance of Mg2+ ions in the process 
[58]. Moreover, the last steps of the monomer refolding and their association need a reducing 
environment provided by DTT or appropriate GSH/GSSG molar ratios (10:1). Under these 
conditions fully active dimers were produced, although those obtained in the presence of 
GSH/GSSG contained a single disulfide bond (C35r-C61r) as well as several oxidized methionine 
residues [49]. Production of this single disulfide blocks the dimer-tetramer concentration-
dependent equilibrium observed in the fully reduced forms, thus providing further evidence of the 
key role of cysteines in the central domain for association. The presence of copper during 
refolding has also been shown to reduce the production of active MATα1 and MATα2 
oligomers, although no effect on the association state attained was observed [59].  
 Unfolding experiments revealed a rapid loss of AdoMet synthesis at very low urea 
concentrations, a process that preceded dimer dissociation [55]. In addition, structural 
information indicated that urea unfolding is a two-step process in which a monomeric 
intermediate (I) can be identified [55, 60]. The main characteristics of this state are: i) its lack of 
activity; ii) the conservation of a 70% of the secondary structure composition; and iii) some 
features of a molten globule. In addition, this intermediate exhibited reduced ANS binding 
capacity as compared to the native dimer, therefore suggesting exposure of a smaller hydrophobic 
surface to the solvent. The reversibility of MAT IIIr folding allowed calculation of the free 
energy of the process that is 65.69 kJ/mol. Kinetic experiments showed later the existence of a 
second short-lived intermediate (Ik2) between I and the dimer that is supposed to be monomeric, 
although its precise association state has not been demonstrated [60]. Furthermore, tetramer to 
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dimer dissociation also occurs through a kinetic intermediate (Ik1) that was detected following 
ANS fluorescence. This new state was suggested to be a dimer just before undergoing the 
conformational changes that differentiate MAT I and MAT III dimers [49]. The fact that this 
process can be followed by ANS fluorescence indicates that the dye binds near the 
tetramerization area, this site being identified as the 358PG359 dipeptider and the 131VGA134 stretchr 
located to the beginning of the active site loop. The free energy of tetramerization was calculated 
to be 29.24 kJ/mol and that of the overall process 102.14 kJ/mol, thus showing that the main 
contribution to the oligomer stability derives from monomer-monomer association. 
 Recently the stability of the highly divergent MATMj has been explored using urea and 
single tryptophan mutants at several secondary structure elements [56]. Despite its highly 
divergent sequence, MATMj seems to preserve the topology and structural features of the rest of 
the family, and hence some data can be extrapolated. Thus, although MATMj exhibits 
substantially higher stability than the mesophilic MATs, the structural elements more susceptible 
to urea denaturation are the exposed areas of three β-sheets at the flat contact surface between 
monomers, dimer dissociation requiring a wider perturbation involving the three domains of the 
molecule. In order to achieve higher stability the access of the denaturant to the monomer 
interface should be limited. Structural predictions show a tighter binding between monomers of 
MATMj as compared to MATr [56], and crystal structures illustrate that the active site cavity is 
much wider in MATr than in the E. coli counterpart [23]. Extrapolation of these data to MATr 
suggests that urea access to analogous secondary structure elements is easier and that a larger 
portion of the β-sheets is exposed to the denaturant because of a wider active site. Thus, a more 
important perturbation of the β-sheets can be expected, and hence the rapid loss of activity 
observed in a protein with a low affinity for the substrate KmMet (∼1 mM) and its dissociation at 
inferior urea concentrations. 
 On the other hand, thermal denaturation of MATr is an irreversible process in which 
changes in activity and structure occur in the range 37-55ºC [61]. According to data obtained by 
two-dimensional infrared spectroscopy the first elements to undergo unfolding are the most 
solvent exposed, α-helixes and β-turns. Exposure of hydrophobic residues and intersubunit 
hydrogen bonds are the second events that lead to final aggregation. These results could be a 
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consequence of two phenomena, dimer dissociation and monomer aggregation or direct 
aggregation of unfolded dimers.  
 The only in vivo folding data available refer to MATc, which has been identified among 
the substrates of the GroEL/GroES chaperonin system [62]. Several authors have indicated that 
the capacity of the active site cavity of this chaperonin would be able to admit proteins no larger 
than ∼50 kDa, thus precluding the folding of MAT dimers in its inner space. The combined data 
available suggest that a monomeric intermediate (analogous to I) can be folded by the 
chaperonin, and such a monomer, according to ANS binding results, may expose a smaller 
hydrophobic surface to the solvent than the final dimer. Thus, this intermediate will need to 
accomplish some additional conformational changes to allow the establishment of the large 
number of hydrophobic contacts observed among monomers in the dimer. This association step 
may require additional chaperones that remain unidentified, the effects of copper accumulation 
on MAT oligomers suggesting a role for metallochaperones in this step [59]. 
 
6. Post-translational modifications. 
 The identification of post-translational modifications that could regulate MAT behavior 
has been the subject of study for several years, although the information obtained to date is quite 
limited. Most of the data relate to the redox regulation of the protein and have been attained with 
rat MAT I/III. Both in vitro and in vivo studies showed that MAT activity is decreased under 
oxidative conditions due to reductions in the GSH/GSSG ratio [16, 51, 63, 64]. Moreover, redox 
stress induced the accumulation of inactive dimers in animal models [65]. Analysis of the agents 
that let to such behavior revealed MAT inhibition by GSSG, H2O2 and NO, and related this 
inactivation to the production of an intrasubunit disulfide and C121r hydroxylation or 
nitrosylation, respectively [16, 52, 66, 67]. The use of mutants and refolding systems allowed 
identification of C35r and C61r as the residues involved in the disulfide, and showed that 
production of this covalent modification blocks dimer-tetramer exchange [49, 68]. The presence 
of these two cysteines in the central domain suggests that the disulfide may contribute to the 
stabilization of the β-sheet through which interactions for tetramerization are established. Two 
additional cysteines exist in this sheet, C57r and C69r that according to the structural data appear 
at disulfide bond distance but with their sulfhydryl groups facing opposite directions [44]. 
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Although not demonstrated yet, it is possible that folding intermediates in which anomalous 
disulfide patterns are established are favored during oxidative stress, and hence rendering inactive 
species that may or may not associate into dimers. The accumulation of inactive or poorly active 
dimers described during disease or intoxication processes that reduce the GSH/GSSG ratio may 
relate to the production of this kind of oxidized species, an aspect that remains unsolved. 
 Regarding nitrosylation and hydroxylation, the presence of C121r in a flexible loop at the 
active site entrance, has led authors to postulate the putative role of this modification in the 
control of the access of substrates to the catalytic site. This modification has been suggested to 
block the loop in a closed conformation, thus impeding catalysis [52, 66, 67]. The presence of 
acid and basic residues in the proximity of the cysteine to be nitrosylated is a requirement for the 
modification to take place [69]. Such residues have been identified in rat MATα1 as D355r, 
R357r and R363r and its key role further demonstrated by mutation to serine, a substitution that 
led to decreased NO modification. Some of the mutations identified in human persistent 
hypermethioninemia affect the equivalent R356h residue introducing a glutamine or proline in 
this position, and change P357h to leucine. Therefore, impairment in NO-induced regulation of 
MAT I/III activity is expected to occur in these patients. Both C121r nitrosylation and the C35r-
C61r disulfide provide regulatory mechanisms apparently restricted to α1 oligomers, as the 
catalytic α2 subunits lack the equivalent cysteine residues (G120 and A60).  
 In vitro refolding assays in the presence of GSH/GSSG allowed identification of 
methionine residues susceptible to oxidation (amino acids 20r, 65r, 139r and 151r) [49]. However, 
the impact of methionine modification on activity and oligomerization has not been explored 
further. The introduction of additional methionine residues due to human mutations (I322Mh) 
may provide the enzyme with a new oxidation target with higher affinity for modification. The 
location of this residue in the dimer structure and its contribution to the monomer-monomer 
stability may be affected by this substitution, rendering proteins with low activity as reported [34, 
35].  
 Phosphorylation may be another mechanism through which MATs can be regulated [70]. 
Analysis of their sequences revealed several putative phosphorylation sites for a variety of 
kinases, although only PKC modification of MAT I/III at T342r has been demonstrated in vitro 
[71]. One of the mutations identified to date in humans occurs at E344h, residue that is substituted 
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by alanine. Such a change of charge near the phosphorylation site could be key for kinase 
recognition, thus altering the modification pattern. This effect could be also expected to occur in 
other human mutations that also locate next to putative phosphorylation sites, these include: 
R264Hh, K289Nh and G336Rh. However, both R264Hh and K289Nh may not be at truly 
phosphorylation sites due to their location at the active site cavity.  
 
7. Alterations in MAT behavior in disease. 
 Changes in expression, oligomerization and MAT activity have been described in several 
pathologies and animal models of disease (Figure 7). Probably the largest amount of data 
published refers to hepatopathologies related to ethanol abuse and hepatomas, although results 
concerning leukemia and cognitive diseases are also available. Several authors have reported 
reductions in MAT1A mRNA levels during human alcoholic cirrhosis, although discrepancies 
about MAT2A transcript levels have been published. Thus, Avila et al. showed no induction of 
MAT2A by ethanol [72], whereas other studies reported increases in MAT2A expression, an 
effect mediated by TNFα [73]. In parallel, decreases in MAT activity and accumulation of dimers 
have been described that correlate with the corresponding reductions in AdoMet concentration 
[65, 74-77]. In contrast, differences in the effects on AdoHcy production among models occur, 
although the net effect in the methylation index (AdoMet/AdoHcy ratio), a decrease, is the same. 
Liver damage during ethanol consumption may be derived from the impairment of methylation 
reactions and GSH-dependent detoxification capacity. Reductions in GSH levels and increases in 
protein nitrosylation are known to take place in these cases, effects to which MAT I/III is 
susceptible. Other protein modifications caused by products of ethanol catabolism cannot be 
excluded, although this aspect has not been analyzed. Several reports have shown also that 
treatment with AdoMet attenuates ethanol liver injury [75], thus highlighting the importance of 
MAT function in the development of cirrhosis. 
 In the early 70s, Halpern et al. described the high dependence of human cancer cells on 
exogenous methionine for growth, whereas normal cells can use Hcy instead [78]. Therefore, the 
interest in understanding the alterations caused in the methionine cycle during carcinogenesis 
grew in order to search for useful drugs against this pathology. This search was conducted using 
a variety of carcinogens in animal models in which the effects exerted by the drugs in this 
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pathway were analyzed [79-85]. The results obtained showed a shift from MAT1A to MAT2A 
expression, reflected by reductions in MAT1A mRNA, protein and activity, and the 
corresponding increases in these parameters for MAT2A. The preferential expression of the α2 
catalytic subunit renders a decrease in AdoMet levels that correlates with a global DNA 
hypomethylation [86]. This relationship with hepatocellular carcinoma (HCC) was further 
confirmed with the production of a MAT1A knockout mouse that spontaneously develops the 
disease [87], and reinforced by the observation that AdoMet therapy is efficient in preventing 
HCC [88]. In contrast, silencing of MAT2A expression in normal or MAT1A-overexpressing 
hepatoma cells produced cell death [89]. MAT2B provides a growth advantage to hepatoma cells, 
and its overexpression is normally associated with hepatic dysfunction [90]. In all these processes 
iNOS induction increases NO production leading not only to MAT I/III inactivation, and hence to 
a reduction in AdoMet concentration, but also to effects on several transcription factors that may 
control the switch among MATs [79]. 
 Wilson’s disease is another interesting pathology in which copper is accumulated in the 
liver due to mutations in the ATP7B transporter, thus leading to redox stress, among other 
effects. Several animal models of the disease exist and in one of them, Long Evans Cinnamon 
rats (LEC), changes in MAT activity and AdoMet levels were described at late stages of disease 
[91]. Several years later Delgado et al. examined the changes in the methionine cycle in this 
model but at early stages of copper accumulation, and showed changes in the expression pattern 
of the MAT isoenzymes [59]. In 9 week-old animals, a switch between MAT1A and MAT2A 
expression was already detected, but surprisingly MAT2B followed the opposite trend to 
MAT2A decreasing by 80%. Copper effects on MAT2B expression were also shown to rely on 
redox mechanisms in experiments carried out in cell culture. The changes in MAT1A expression 
correlated with decreases in protein, AdoHcy and GSH levels, the net result being an increase in 
the methylation index and a decrease in the GSH/GSSG ratio. As observed in other pathologies, 
copper accumulation also modified the MAT I/III ratio, but in this case reductions in dimer 
content were observed. Analysis of the effect of copper on MAT isoenzymes in vitro confirmed 
inhibition of the enzyme activity and showed the influence of this metal in folding of the 
subunits. Recombinant MATα2h oligomer activity was more susceptible to metal inactivation 
than that of MATα1r oligomers [59]. 
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 Patients suffering from several neurological diseases are known to display alterations in 
transmethylation reactions [92-96], and several animal models showed an association between 
methionine synthesis and/or MAT activity and development of myelopathies, ataxia and other 
related diseases [97-99]. Parkinson’s patients show low AdoMet and AdoHcy levels in blood and 
increased erythrocyte MAT activity [95], although no relationship with age and duration of the 
disease has been reported. L-dopa treatment induces a short-term increase in hepatic and brain 
MAT expression and activity, as well as in AdoMet levels [100], but AdoMet depletion is 
observed in long therapies [101-105]. 
 Currently, newborn screenings for the detection of hypermethioninemia are carried out all 
over the world. Most of the cases identified are due to defects in CBS, fumaryl acetoacetate 
hydrolase (tyrosinemia type I) or liver disease, however in a small number of patients this 
alteration is due to mutations in the MAT1A or GNMT genes [105]. The first patient with isolated 
persistent hypermethionemia due to MAT1A mutation was reported in 1974 [106], and ever since 
new mutations have been identified, a summary of which is included in Table 1. Many patients 
are asymptomatic, but in a few cases neurological defects have been noticed. The most severe 
cases present demyelination and correspond to mutations that introduce early stop codons in the 
MAT1A ORF, leading to subunits of ∼350 amino acids. One of these patients was treated with 
AdoMet and an improvement in demyelination was reported, thus suggesting that these 
symptoms derive from low AdoMet production [94]. In addition, former experiments using 
cycloleucine, a MAT inhibitor, in rats showed development of myelin abnormalities that were 
prevented by AdoMet [107]. All these data together and the absence of such symptoms in 
patients exhibiting shorter forms of the α1 protein led Hazelwood et al. [36] to propose the 
hetero-oligomerization hypothesis, which will be discussed in the last section of this chapter to 
explain the origin of the disease. This hypothesis presented a conceptual problem at the time of 
its proposal that was related to the restricted expression pattern known for MATI/III (considered 
hepatic only) and alterations in the nervous system, where only MAT II was known to exist.  
 
8. MAT tissular distribution and subcellular localization. 
 Early data on MAT tissue-specific expression derived mostly from activity measurements 
carried out in samples from different tissues at two methionine concentrations (to distinguish 
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among MAT isoenzymes with different KmMet) and in the presence of DMSO (a known activator 
of MAT III). The same is true for the subcellular distribution that was analyzed in fractionation 
experiments. All these data established the extrahepatic presence of MAT II, together with the 
hepatic expression of MAT I/III in normal tissues. This postulate was reassessed in the last 
decade using Northern and Western blot and real time PCR. The compiled results confirmed the 
broad MAT2A and MAT2B expression [90] and a wide distribution for MAT1A that exceeds 
normal adult liver [28]. The expression levels correlated with early results: i) very high for 
MAT1A in liver followed by pancreas [28]; ii) high for MAT2B in spleen, heart, lung and very 
low in normal adult liver [90]; and iii) high in extrahepatic tissues, fetal liver and hepatoma for 
MAT2A [5]. Subcellular distribution was also thought to be restricted to the cytosol and 
fluorescence microscopy confirmed this localization for the β subunit [90]. However, recent 
studies by immunohistochemistry, confocal fluorescence microscopy, subcellular fractionation 
and western blot showed MATα1 in the cytosol of hepatocytes and pancreatic cells but also in 
the nucleus of almost every cell type analyzed [28]. Thus, the question arises as to which may be 
the biological role for this distribution. 
 Nuclear MATα1r was mainly monomeric, although a small amount of active tetramers 
could be detected in this compartment in liver [28]. The protein colocalized with nuclear matrix 
markers and both nuclear distribution and matrix localization were independent of AdoMet 
synthesis capacity, the inactive F251Dr mutant showing the same pattern than the wild type 
protein. Basic residues in the C-terminal domain were shown to be involved in the 
nucleocytoplasmic distribution, and two partially overlapping areas were identified that are 
implicated in localization. One area delimited by amino acids 313r, 368r, 369r and 392r was 
related to cytosolic retention, whereas that comprised by residues 340r, 344r and 393r was linked 
to nuclear localization. The subcellular distribution of a truncated protein at residue 351Xr, 
analogous to some of the mutants detected in human patients with hypermethioninemia, was also 
examined. This shorter form appeared mainly in the nucleus and colocalized with the nuclear 
matrix marker SC-35. The use of mutants showing preferential nuclear or cytosolic localization 
allowed correlation of nuclear MATα1r distribution with increases in specific epigenetic 
modifications (H3K27 trimethylation) [28]. This result suggested the need for the presence of 
active nuclear MATα1 oligomers to guarantee specific methylations, and opened the possibility 
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of additional unknown functions for the nuclear monomers. Moreover, identification of the areas 
responsible for nucleocytoplasmic distribution close to the in vitro phosphorylated T342r residue 
deserve additional studies to determine the role that such modification may have in the control of 
MAT subcellular localization. Additionally, both the nucleocytoplasmic distribution and its 
putative control by phosphorylation may be altered in patients with mutations in these areas, such 
as those related to E344h and G336h residues which induce charge changes at the molecular 
surface (Table 1).  
 
9. Hazelwood’s hypothesis of MAT hetero-oligomerization in demyelination. 
 The observation of demyelination exclusively in patients with MAT1A mutations leading 
to subunits ∼350 amino acids long, together with the improvement observed in the symptoms of 
one of this patients upon AdoMet treatment let Hazelwood et al. propose that truncated α1 
subunits may hetero-oligomerize with α2 monomers sequestering them in an inactive oligomer, 
and hence producing a decrease in AdoMet levels [36]. This decreased concentration of the 
methyl donor will lead to the corresponding lack of methylation products, among them 
phosphatidylcholine and creatine, important for neural sheath [108] and neural structure [109]. 
Thus, administration of AdoMet would allow recovery of normal intracellular levels of the 
methyl donor, and hence the improvement observed in the patient symptoms [94]. This 
hypothesis was postulated in 1998 when only the MATc crystal structure was available [45], and 
the importance of the R264 residue in dimerization was known. Preservation of this arginine and 
the high homology among α1 and α2 human sequence (84%) seemed enough to consider hetero-
oligomerization plausible. Now when more MAT structures are available [23], it is known that 
monomers may have slightly different orientations between each other in different species [44], 
and the impact of these truncations on the monomer subunit and the intersubunit interactions in 
the dimer can be reexamined. Thus, truncated subunits will lack approximately half of the C-
terminal domain, specifically the area mostly related to the monomer surface. The impact this 
deficiency will have in folding of the remaining C-terminal domain structure, including the β-
sheet that participates in monomer-monomer contacts, is unknown. However, this fact will force 
a rearrangement of the region to hide amino acids that will become otherwise exposed. Moreover, 
the 351X mutant not only suffers the truncation of part of this domain, but also a change in its 
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sequence that affects a ∼15% of the central domain. This means an almost completely different 
C-terminal domain, and hence making preservation of its structure and interaction pattern 
unlikely (Figure 5).  
 As mentioned in previous sections, the last years have also seen some in vitro folding 
studies that showed the need of populating a monomeric intermediate I to attain the final active 
structure. The appropriate conformation of this intermediate will allow the final changes in the 
subunit structure and the association into active oligomers. The importance of this intermediate 
may require chaperonin assisted folding, as deduced from the finding of MATc as a substrate of 
the GroEL/GroES system [62]. To date, it is not known if truncated MATs will achieve a similar 
intermediate state allowing association with the α2 subunits. Moreover, if additional chaperones 
are needed to catalyze the last folding and association steps, the possibility exists that the 
modifications concerning the C-terminal domain may preclude recognition or achievement of a 
structure resembling at least part of the wild type structure (N-terminal and central domains). 
Even if the truncated monomer is able to oligomerize, two association scenarios can be 
considered: i) correct hetero-oligomerization, which should render a dimer with one complete 
active site (from the two in the molecule); and ii) an hetero-oligomerization pattern different from 
that in the native dimer, an alteration that will be of special importance for the active sites that 
locate between momoners. Structures of E. coli and mammalian MATs are almost identical, and 
hence overexpression of the truncated forms in bacteria is expected to produce hetero-oligomers 
with MATc. These experiments were performed and no MAT activity was reported by 
Chamberlin et al. [30]. In our hands, overexpression of a 351Xr mutant let to inclusion body 
production, thus suggesting incorrect folding of this type of subunit [28].  
 Another problem of Hazelwood’s hypothesis at the time of its proposal was derived from 
the identification of MATα1 oligomers only in liver. Now that expression of MAT1A has been 
proven in other tissues [28], this problem no longer exists, although new aspects have to be 
considered. First, the putative interaction of inappropriately folded truncated species with 
proteins other than the α2 subunits should be taken into account. Such anomalous interactions 
may be responsible for the observed symptoms. Second, MATα1 expression in extrahepatic 
tissues occurs mainly in the cell nucleus, where most of the protein appears as monomers. A 
truncated form similar to that of patients with demyelination showed its preferential accumulation 
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in the nucleus in several cell types, thus suggesting that the effects observed may derive from the 
functions MAT is exerting in that particular compartment. To date we only know that nuclear 
accumulation of MATα1 correlates with H3K27 trimethylation, an epigenetic modification 
related to gene repression. Accumulation of truncated mutants in the nucleus will either favor this 
modification (i. e. repressing myelin related genes) or interfere with this methylation due to 
anomalous binding of MATα1 truncated species that are incorrectly folded. Finally, the 
hypothesis did not consider α2β interactions. No data exist about how these subunits interact, 
neither of the role of spliced β-subunit variants, and hence of the effect that α2-truncated α1 
hetero-oligomerization may exert in recognition of the regulatory subunit.  
 
CONCLUSION  
 The knowledge on MAT structure, catalytic mechanism and regulation has increased 
enormously during the last decades. However, this accumulated information has provided no clue 
to the relationship between some MAT1A mutations and the demyelination observed in patients 
expressing the corresponding truncated forms. The main aspects that remain to be clarified to 
understand this relationship include: i) the structure of the truncated protein subunits; ii) its 
oligomerization abilities with either α2 and β subunits; iii) understanding the in vivo folding 
pathway for MATs and the chaperones/chaperonines involved; iv) the effect of nuclear 
accumulation of truncated subunits in cellular behavior (i.e. myelin production); and, v) 
elucidation of the nuclear functions of MATα1, and hence of its alterations due to truncations. In 
addition, the putative existence of MAT I/III moonlighting related to its presence in to date new 
subcellular locations, and hence the effect that mutations could have on these additional functions 
cannot be underestimated. Thus, the number of questions related to MATs that await an answer is 
increasing, despite the large effort made to date to get insight the knowledge of the relationship 
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Figure 1. Reactions involving S-adenosylmethionine. The figure summarizes the reactions in 
which S-adenosylmethionine participates in any kind of cell organized according to the group 
that is transferred in each case. S-adenosylhomocysteine (SAH) and S-adenosylmethioninamine 
are intermediates in some of these processes. 
 
Figure 2. The methionine cycle in mammalian liver. The first step of methionine metabolism 
is the synthesis of S-adenosylmethionine by methionine adenosyltransferases (MATs). This 
compound is used as methyl donor by a large number of methyltransferases (MTase), and among 
them glycine N-methyltransferase (GNMT), leading to methylated acceptors and S-
adenosylhomocysteine. This demethylated compound is degraded by S-adenosylhomocysteine 
hydrolase (SAHH), in the only reversible reaction of the cycle, to render adenosine and 
homocysteine. Methionine can then be resynthesized from homocysteine by methylations 
catalyzed by methionine synthase (MS) and betaine homocysteine methyltransferase (BHMT) that 
use 5-methyltetrahydrofolate (MTHF) and betaine as methyl donors, respectively. MTHF is 
synthesized by methylene tetrahydrofolate reductase (MTHFR) an enzyme inhibited by S-
adenosylmethionine. Homocysteine can enter also the trans-sulfuration pathway, where it is 
converted to cystathionine by cystathionine β-synthase (CBS). 
 
Figure 3. Organization of the MAT amino acid sequence among structural domains and 
impact of human deletions and sequence extensions. The figure shows the sequence stretches 
involved in each domain, the percentage of contribution in each case appearing below. The 
impact of human mutations leading to truncated or extended monomers is also shown. Changes 
from the wild type sequence are indicated in magenta. 
 
Figure 4. Impact of truncations in the monomer structure. The figure shows the structural 
elements of each domain preserved in the truncated human MATs; N-terminal (blue), central 
(red) and C-terminal (green) domains.  
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Figure 5. The human 351X mutant changes a large stretch of its C-terminal sequence. The 
827insG in the human MAT1A ORF leads not only to an early stop codon, but also to a complete 
change in the reading frame, and therefore in the sequence starting on residue 276. Comparison 
of the resulting sequence and the wild type is shown in the upper part of the figure, whereas the 
lower part depicts the effect of the sequence changes in the side chains (residues 271-stop) is 
depicted. The last common amino acids (271-275) appear in cyan and blue for the wild type and 
351X C-terminals, respectively. 
 
Figure 6. The human MATα1 dimer. The figure shows the expected structure for the human 
α1 dimer created by mutation in the rat sequence of the 1QM4 pdb file; the sequences of both 
proteins are 95% identical. Monomer A surface appears in blue, the areas of contact with 
monomer B (salmon) being shown in gray. The three β-sheets of monomer B (one contributed 
per domain) appear oriented against the contact areas of monomer A. The arrow indicates the 
entrance to one of the active sites of the molecule. 
 
Figure 7. Summary of the knowledge on MAT regulation. The scheme represents the different 
levels (mRNA, protein and activity) reported for MAT regulation during disease or under several 
treatments. Black dashed arrows indicate increases, whereas red dashed arrows stand for 
decreases in any of the parameters examined. Abbreviations correspond to: superantigen 
staphylococcal enterotoxin B (SEB); S-adenosylmethionine (AdoMet); methylthioadenosine 
(MTA); phytohemagglutinin (PHA); interleukin 2 (IL-2); interleukin 6 (IL-6); lipopolysaccharide 
(LPS); buthionine sulfoximine (BSO); oxidized glutathione (GSSG); 3-morpholinosydnonimine 



























I C65T S22L HO1   110] 
G113A S38N CHE2 No activity5 68% 35, 111 
T125C L42P HO   110 
 
II 
 C164A A55D CHE 17%4  34 
G205A G69S    42 
255delCA 92X CHE No activity5  35, 111 
 
III 
  G98S HO 100% activity4,5                                                                    35 
C426T A142 CHE   34 V 
 539insTG 185X HO, CHE  7% 30, 36 
C595T R199C CHE, HO 10% activity5  30 VI 
 C745T R249W    42 
G791A R264H  <1% activity4,5 
monomer 
low 35, 37-39, 
42, 43 
G791T R264C CHE No activity5  35 
C790T R264C    42 
G867T K289N    42 
G870A V290 CHE   34 






827insG 351X HO No activity5  30 
T966G I322M HO, CHE 21%4,5  34, 35 
G1006A G336R CHE 23% activity5  35 
A1031C E344A CHE 12%5  35 
1043,1044del 350X HO No activity5  30, 40 
G1067A R356Q CHE 53% activity5 low 30, 112 






C1070T P357L CHE 31%4  34, 42 
T1131C Y377 CHE   34 
G1132A G378S CHE 0.1% activity5  30, 41, 112 






G1188T X396YfsX464    42 
1HO, homozygosis 
2CHE, compound heterozygosis 
3Mutant activity levels versus wt protein upon COS-14 or E. coli5 overexpression  
6Measured in liver biopsies 
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